Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 91 AL 105

Modulating 5-HT(4) and 5-HT(6) receptors in Alzheimer's disease treatment

Lalut J, Karila D, Dallemagne P, Rochais C.

Future Med Chem. 2017 May;9(8):781-795. doi: 10.4155/fmc-2017-0031. Epub 2017 May 15.

Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease

Bhounsule AS, Bhatt LK, Prabhavalkar KS, Oza M.

Brain Res Bull. 2017 Jun;132:28-38. doi: 10.1016/j.brainresbull.2017.05.006. Epub 2017 May 17.

The Mechanisms of Action of Curcumin in Alzheimer's Disease

Tang M, Taghibiglou C.

J Alzheimers Dis. 2017;58(4):1003-1016. doi: 10.3233/JAD-170188.

Pharmacological treatment of Alzheimer's disease in the population of Catalonia, Spain

Obach M, Lopez P, Catalan A.

Med Clin (Barc). 2017 Jul 21;149(2):86-87. doi: 10.1016/j.medcli.2017.03.030. Epub 2017 May 17.

Luteolin as a potential preventive and therapeutic candidate for Alzheimer's disease

Kwon Y.

Exp Gerontol. 2017 Sep;95:39-43. doi: 10.1016/j.exger.2017.05.014. Epub 2017 May 17.

Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b

Huang W, Li Z, Zhao L, Zhao W.

Biomed Pharmacother. 2017 Aug;92:46-57. doi: 10.1016/j.biopha.2017.05.060. Epub 2017 May 18.

Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease

Qiu WQ.

Neuroscience. 2017 Jul 25;356:44-51. doi: 10.1016/j.neuroscience.2017.05.024. Epub 2017 May 19.

Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease

Agrawal M, Ajazuddin, Tripathi DK, Saraf S, Saraf S, Antimisiaris SG, Mourtas S, Hammarlund-Udenaes M, Alexander A.

J Control Release. 2017 Aug 28;260:61-77. doi: 10.1016/j.jconrel.2017.05.019. Epub 2017 May 24.

Targeting Free Radicals in Oxidative Stress-Related Human Diseases

Poprac P, Jomova K, Simunkova M, Kollar V, Rhodes CJ, Valko M.

Trends Pharmacol Sci. 2017 Jul;38(7):592-607. doi: 10.1016/j.tips.2017.04.005. Epub 2017 May 24.

Biosensors for Screening Kinase Inhibitors

Bhalla N, Estrela P.

Curr Top Med Chem. 2017;17(22):2470-2481. doi: 10.2174/1568026617666170531113233.

Can Co-Activation of Nrf2 and Neurotrophic Signaling Pathway Slow Alzheimer's Disease?

Murphy KE, Park JJ.

Int J Mol Sci. 2017 May 31;18(6):1168. doi: 10.3390/ijms18061168.

The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models

Amit T, Bar-Am O, Mechlovich D, Kupershmidt L, Youdim MBH, Weinreb O.

Neuropharmacology. 2017 Sep 1;123:359-367. doi: 10.1016/j.neuropharm.2017.05.026. Epub 2017 May 29.

Estrogen and Alzheimer's disease: Still an attractive topic despite disappointment from early clinical results

Merlo S, Spampinato SF, Sortino MA.

Eur J Pharmacol. 2017 Dec 15;817:51-58. doi: 10.1016/j.ejphar.2017.05.059. Epub 2017 May 31.

The underexplored question of β-amyloid monomers

Copani A.

Eur J Pharmacol. 2017 Dec 15;817:71-75. doi: 10.1016/j.ejphar.2017.05.057. Epub 2017 May 31.

Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease

Stonnington CM, Harel B, Locke DEC, Hentz JG, Zhang N, Maruff P, Caselli RJ.

Alzheimer Dis Assoc Disord. 2017 Oct-Dec;31(4):271-277. doi: 10.1097/WAD.0000000000000200.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias